Senate LDA lobbying filing

TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY)

Registrant: TIBER CREEK GROUP Year: 2024 Period: Fourth Quarter Type: Q4

View on lda.senate.gov ↗

Reported income

$80.0K

Reported expenses

not reported

Tracked program mentions1

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

Amphibious Combat Vehicle Family of Vehicles2025matched: “2025”PE code cited directly
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the…

Lobbying activities3

Copyright/Patent/TrademarkCPT
Issues related to intellectual property; S.150 - Affordable Prescriptions for Patients Act of 2023; S.3583 - A Bill to Address Patent Thickets.
Health IssuesHCR
Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R.4818/S.2407 - Treat and Reduce Obesity Act of 2023.
Medicare/MedicaidMMM
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues relating to H.R.10545 - American Relief Act, 2025 (PL 118-158).

Lobbyists5

COREY MALMGREN
EMILY KIRLIN
JOHN GONZALEZ
JONATHON JONES
TIMOTHY MOLINO

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.